Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 7;21(10):3261–3267. doi: 10.1245/s10434-014-3908-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2014

Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

PMC Copyright notice

Fig. 1 — a pCR rates and major subtype re-assignments for patients classified by BluePrint/MammaPrint molecular subtyping compared with IHC/FISH assessed subgroups. The analysis includes only patients treated with NCT (n = 403). The two major subtype reassignments were (A) conventional luminal (HR+/HER2−) patients, 35 of 188 (19 %) patients reclassified by BluePrint as Basal (arrow A) and (B) conventional HER2+ patients, 36 of 123 (29 %) reclassified by BluePrint as Luminal (arrow B). b pCR rates and major subtype reassignments for conventional HER2+/HR+ (“triple positive”) patients (95 % treated with NCT/trastuzumab). Thirty-six of 75 (48 %) of conventional HER2+/HR+ patients were reclassified by BluePrint as Luminal—with only 1 pCR (3 %) to NCT (arrow A). Thirty-three of 75 (44 %) of conventional HER2+/HR+ patients were classified by BluePrint as HER2, with a pCR rate to NCT of 45 % (arrow B). Six conventional HER2+/HR+ patients were reassigned to BPBasal (not shown)